Using 400 real-world patient cases, the CARE platform correctly classified 99.5 percent of cases according to NCCN guidelines ...

The EC granted conditional approval based on activity seen in a subset of IHC 3+ HER2-positive advanced biliary tract cancer patients in a Phase II trial.

The firm hopes that ETX-636's dual mechanism inhibiting mutant PI3Kα will give it an edge over competing products on the market.

The biotech has received written agreement from the agency through the START pilot program on key aspects of its trial design for evaluating NGN-401.

With an FDA IND clearance, the firm will test IKS014 as an alternative for HER2-positive solid tumor patients in the US who have relapsed on other therapies.

After an abnormal NIPT finding in a pregnant woman, a maternal-fetal medicine doctor orders a second NIPT, against recommendations.

NEW YORK – Imagene AI on Tuesday said it closed a $23 million Series B financing round to advance its multi-modal digital pathology foundation models for precision medicine. Oracle Chairman and CTO ...

Rutgers New Jersey Medical School has rolled out routine blood tests for the cardiovascular biomarker at another one of its affiliated hospitals.

The firms are planning two clinical trials of the anti-CTLA-4 agent muzastotug in colorectal cancer and in solid tumors.